Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Trial · NCT02368886
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3 | Regorafenib Dose Escalation Group | 0.43 | 95% Confidence Interval 0.29 to 0.56 | proportion of patients | |
| Proportion of Patients in Each Arm Who Complete 2 Cycles of Protocol Treatment and Initiate Cycle 3 | Regorafenib Standard Dose Group | 0.26 | 95% Confidence Interval 0.15 to 0.37 | proportion of patients | |
| Overall Survival (OS) | Regorafenib Dose Escalation Group | 9.8 | 95% Confidence Interval 7.5 to 11.9 | months | |
| Overall Survival (OS) | Regorafenib Standard Dose Group | 6.0 | 95% Confidence Interval 4.9 to 10.2 | months | |
| Progression Free Survival (PFS) | Regorafenib Dose Escalation Group | 2.8 | 95% Confidence Interval 2.0 to 5.0 | months | |
| Progression Free Survival (PFS) | Regorafenib Standard Dose Group | 2.0 | 95% Confidence Interval 1.8 to 2.8 | months | |
| Time to Progression (TTP) | Regorafenib Dose Escalation Group | 2.8 | 95% Confidence Interval 1.9 to 5.7 | months | |
| Time to Progression (TTP) | Regorafenib Standard Dose Group | 2.0 | 95% Confidence Interval 1.8 to 3.3 | months | |
| Cumulative (Total) Dose of Regorafenib Received by Patients in the First Two Cycles | Regorafenib Dose Escalation Group | Cycle 1 | 91.8 | Standard Deviation 33.4 | mg/day |
| Cumulative (Total) Dose of Regorafenib Received by Patients in the First Two Cycles | Regorafenib Standard Dose Group | Cycle 1 | 133.1 | Standard Deviation 34.6 | mg/day |
| Cumulative (Total) Dose of Regorafenib Received by Patients in the First Two Cycles | Regorafenib Dose Escalation Group | Cycle 2 | 121.3 | Standard Deviation 40.0 | mg/day |
| Cumulative (Total) Dose of Regorafenib Received by Patients in the First Two Cycles | Regorafenib Standard Dose Group | Cycle 2 | 117.3 | Standard Deviation 48.9 | mg/day |
| Dose Intensity of Regorafenib Received by Patients in the First Two Cycles as Measured by the Percentage of Planned Dose Received | Regorafenib Dose Escalation Group | 76.2 | Standard Deviation 25.3 | percentage of planned dose received | |
| Dose Intensity of Regorafenib Received by Patients in the First Two Cycles as Measured by the Percentage of Planned Dose Received | Regorafenib Standard Dose Group | 76.0 | Standard Deviation 21.0 | percentage of planned dose received | |
| Proportion of Patients Overall and Within Each Arm Experiencing Grade 3 or 4 Hand and Foot Syndrome (HFS) | Arm A1 (Regorafenib Dose Escalation + Pre-emptive Strategy) | 0.1786 | 95% Confidence Interval 0.0606 to 0.3689 | proportion of participants | |
| Proportion of Patients Overall and Within Each Arm Experiencing Grade 3 or 4 Hand and Foot Syndrome (HFS) | Arm A2 (Regorafenib Dose Escalation + Reactive Strategy) | 0.1154 | 95% Confidence Interval 0.0245 to 0.3015 | proportion of participants | |
| Proportion of Patients Overall and Within Each Arm Experiencing Grade 3 or 4 Hand and Foot Syndrome (HFS) | Arm B1 (Regorafenib Standard Dose + Pre-emptive Strategy) | 0.1515 | 95% Confidence Interval 0.0511 to 0.3190 | proportion of participants | |
| Proportion of Patients Overall and Within Each Arm Experiencing Grade 3 or 4 Hand and Foot Syndrome (HFS) | Arm B2 (Regorafenib Standard Dose + Reactive Strategy) | 0.1724 | 95% Confidence Interval 0.0585 to 0.3577 | proportion of participants | |
| Quality of Life (QOL) (According to the HFS14 Total Score) | Arm A1 (Regorafenib Dose Escalation + Pre-emptive Strategy) | 20.8 | Standard Deviation 19.05 | score on a scale | |
| Quality of Life (QOL) (According to the HFS14 Total Score) | Arm A2 (Regorafenib Dose Escalation + Reactive Strategy) | 29.5 | Standard Deviation 21.97 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02368886/results